×
About 1,363 results

ALLMedicine™ Graves Disease Center

Research & Reviews  446 results

Incidence, Risk Factors, and Outcomes of Incident Atrial Fibrillation in Patients With ...
https://doi.org/10.1016/j.mayocp.2022.12.013
Mayo Clinic Proceedings; Naser JA, Pislaru SV et. al.

Mar 16th, 2023 - To describe the incidence, risk factors, and outcomes of incident atrial fibrillation (AF) in Graves disease (GD). Patients with GD between January 1, 2009, and December 31, 2019, were included retrospectively. We defined GD-related AF as AF diagn...

A 46-Year-Old Woman with a 4-Year History of Graves Disease, with Severe Corticosteroid...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939848
The American Journal of Case Reports; Almazrouei O, Alalawi F et. al.

Feb 16th, 2023 - BACKGROUND Tocilizumab is a therapeutic biologic antagonist of the interleukin-6 (IL-6) receptor that has been approved to treat some autoimmune and chronic inflammatory diseases. This report is of a patient with a history of Graves disease and se...

Hurthle Cell Carcinoma (Oncocytic Carcinoma)
https://emedicine.medscape.com/article/279462-print

Feb 7th, 2023 - Practice Essentials Hürthle cell carcinoma of the thyroid gland is an unusual and relatively rare type of differentiated thyroid cancer.[1] Hürthle cell cancer accounts for only about 3-10% of all differentiated thyroid cancers; therefore, few ins...

Hurthle Cell Carcinoma (Oncocytic Carcinoma)
https://emedicine.medscape.com/article/279462-overview

Feb 7th, 2023 - Practice Essentials Hürthle cell carcinoma of the thyroid gland is an unusual and relatively rare type of differentiated thyroid cancer. [1] Hürthle cell cancer accounts for only about 3-10% of all differentiated thyroid cancers; therefore, few in...

Hurthle Cell Carcinoma (Oncocytic Carcinoma)
http://emedicine.medscape.com/article/279462-overview

Feb 7th, 2023 - Practice Essentials Hürthle cell carcinoma of the thyroid gland is an unusual and relatively rare type of differentiated thyroid cancer. [1] Hürthle cell cancer accounts for only about 3-10% of all differentiated thyroid cancers; therefore, few in...

see more →

Clinicaltrials.gov  21 results

Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
https://clinicaltrials.gov/ct2/show/NCT05678374

Jan 10th, 2023 - Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to exp...

Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
https://clinicaltrials.gov/ct2/show/NCT05643365

Dec 12th, 2022 - Hyperthyroidism is a clinical syndrome caused by increased thyroid hormone in the blood, it can lead to multiple complications, including cardiac, hepatic, and hematologic system complications. More than 80% of hyperthyroidism are caused by Graves...

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
https://clinicaltrials.gov/ct2/show/NCT05532072

Sep 8th, 2022 - Project basis: Thyroid-associated ophthalmopathy (GO), a vision-threatening autoimmune disease, is the most common extrathyroidal manifestation of Graves disease. At present, GO treatment is still dominated by hormone therapy. From 2010 to 2018, t...

Observation in the Treatment of Graves' Disease
https://clinicaltrials.gov/ct2/show/NCT05043233

Sep 14th, 2021 - Graves' disease is the main cause of clinically hyperthyroidism, accounting for about 75% to 80%, and it occurs in women of childbearing age. Clinical manifestations include: high eating, weight loss, sweating, palpitations, emotional excitement a...

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT02311361

Apr 20th, 2021 - Background: Tremelimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Anti-CTLA4 therapy has been shown to enhance anti-tumor immunity by blocking tumor-induced immune suppression of cytotoxic T cells. Durv...

see more →

News  77 results

High Bone Density Found in Women With Hypoparathyroidism
https://www.medscape.com/viewarticle/983455

Nov 3rd, 2022 - The study covered in this summary was published on Research Square as a preprint has not yet been peer reviewed. Key Takeaway Among women with hypoparathyroidism, bone mineral density (BMD) was increased, and there was no increase in fracture risk...

Nail Changes Associated With Thyroid Disease
https://www.mdedge.com/dermatology/article/256823/hair-nails/nail-changes-associated-thyroid-disease
Angela Rosenberg, OMS-IV, Shari R. Lipner, MD, PhD

Aug 4th, 2022 - The major classifications of thyroid disease include hyperthyroidism, which is seen in Graves disease, and hypothyroidism due to iodine deficiency and Hashimoto thyroiditis, which have potentially devastating health consequences. The prevalence of.

Is Long-Term Antithyroid Use the Best Treatment for Graves Disease?
https://www.medscape.com/viewarticle/973869

Jul 7th, 2022 - This transcript has been edited for clarity. Angela Leung, MD, MSc: Welcome to this video commentary about the long-term use of antithyroid drugs in the management of Graves disease. My name is Angela Leung. I'm an adult endocrinologist at the Uni...

Graves Disease, Thyroid Eye Disease, and COVID-19: More Than Meets the Eye?
https://www.medscape.com/viewarticle/972208

Apr 21st, 2022 - Matthew I. Balcerek, BExSci, MBBS COVID-19 has caused disease in close to 500 million people worldwide, according to the World Health Organization. While the airways are its primary target, SARS-CoV-2 may enter many organs via the protein angioten...

Treatment of Elephantiasic Pretibial Myxedema With Rituximab Therapy
https://www.mdedge.com/dermatology/article/252083/dermatopathology/treatment-elephantiasic-pretibial-myxedema-rituximab
Shaan Patel, MD, MBA, David Choi, MD et. al.

Feb 23rd, 2022 - To the Editor: Pretibial myxedema (PTM) is bilateral, nonpitting, scaly thickening and induration of the skin that most commonly occurs on the anterior aspects of the legs and feet. Pretibial myxedema occurs in approximately 0.

see more →

Patient Education  1 results see all →